drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody immunotherapy)
drug_description
Therapeutic monoclonal antibody targeting CCR8 on tumor-infiltrating regulatory T cells, engineered for enhanced ADCC to selectively deplete CCR8+ Tregs and reduce intratumoral immunosuppression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
HC006 is a monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T cells and is Fc-engineered for enhanced ADCC, recruiting FcγR-expressing effector cells (e.g., NK cells) to selectively deplete CCR8+ Tregs in the tumor microenvironment, thereby reducing intratumoral immunosuppression and promoting antitumor immunity.
drug_name
HC006
nct_id_drug_ref
NCT06304571